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The G6PC3 gene encodes the ubiquitously expressed glucose-6-phosphatase enzyme (G-6-Pase β or G-6-Pase 3 or
G6PC3). Bi-allelic G6PC3 mutations cause a multi-system autosomal recessive disorder of G6PC3 deficiency (also
called severe congenital neutropenia type 4, MIM 612541). To date, at least 57 patients with G6PC3 deficiency have
been described in the literature.
G6PC3 deficiency is characterized by severe congenital neutropenia, recurrent bacterial infections, intermittent
thrombocytopenia in many patients, a prominent superficial venous pattern and a high incidence of congenital cardiac
defects and uro-genital anomalies. The phenotypic spectrum of the condition is wide and includes rare manifestations
such as maturation arrest of the myeloid lineage, a normocellular bone marrow, myelokathexis, lymphopaenia, thymic
hypoplasia, inflammatory bowel disease, primary pulmonary hypertension, endocrine abnormalities, growth retardation,
minor facial dysmorphism, skeletal and integument anomalies amongst others. Dursun syndrome is part of this
extended spectrum. G6PC3 deficiency can also result in isolated non-syndromic severe neutropenia. G6PC3 mutations
in result in reduced enzyme activity, endoplasmic reticulum stress response, increased rates of apoptosis of affected
cells and dysfunction of neutrophil activity.
In this review we demonstrate that loss of function in missense G6PC3 mutations likely results from decreased enzyme
stability. The condition can be diagnosed by sequencing the G6PC3 gene. A number of G6PC3 founder mutations are
known in various populations and a possible genotype-phenotype relationship also exists. G6PC3 deficiency should be
considered as part of the differential diagnoses in any patient with unexplained congenital neutropenia.
Treatment with G-CSF leads to improvement in neutrophil numbers, prevents infections and improves quality of life.
Mildly affected patients can be managed with prophylactic antibiotics. Untreated G6PC3 deficiency can be fatal.
Echocardiogram, renal and pelvic ultrasound scans should be performed in all cases of suspected or confirmed G6PC3
deficiency. Routine assessment should include biochemical profile, growth profile and monitoring for development of
varicose veins or venous ulcers.
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Introduction
The glucose-6-phosphatase enzyme catalyzes the final
step of glycogenolysis, hydrolysis of glucose-6-phosphate
in the endoplasmic reticulum (ER). In humans, there are
three glucose-6-phosphatase enzymes encoded by a
gene-family consisting of G6PC1, G6PC2 and G6PC3 [1]
(Figure 1). The enzymes encoded by the three genes, dif-
fer in their expression patterns and kinetic properties.
G6PC1 is expressed in the liver, kidney and small intes-
tine. G6PC2 is expressed mainly in the pancreas and
G6PC3 is ubiquitously expressed. The transport of
glucose-6-phosphate from cytosol to ER is facilitated by
glucose-6-phosphate translocase encoded by ubiqui-
tously expressed SLC37A4.
Bi-allelic G6PC1 mutations cause type 1a glycogen
storage disease (GSD1a, MIM 232200) [2]. GSD1a is
characterized by fasting hypoglycaemia, hepatomegaly,
growth retardation, fasting lactic acidosis, hyperlipid-
aemia and hyperuricaemia. Long-term complications of
GSD1a include hepatic adenomas, pancreatitis, gout,
renal failure, pulmonary hypertension, polycystic ovaries,
osteoporosis, platelet dysfunction, and mild to moderate
learning difficulties [3]. Bi-allelic SLC37A4 mutations re-
sult in glycogen storage disease 1b (GSD1b, MIM
232220) [4]. The phenotype of GSD1b is similar to that
of GSD1a, but patients additionally develop chronic
neutropenia.Figure 1 The glucose-6-phosphatase system. A schematic representatio
displayed in red font, expression sites of the genes are provided within braThe ubiquitously expressed human glucose-6-phosphat-
ase enzyme (G-6-Pase β or G-6-Pase 3 or G6PC3, EC =
3.1.3.9), encoded by the G6PC3 gene, was independently
discovered by two groups in 2003 [5,6]. g6pc3−/− mice
demonstrate neutropenia, defects in neutrophil respiratory
burst, chemotaxis, calcium flux, increased susceptibility to
bacterial infection, elevated plasma glucagon and reduced
plasma cholesterol [7,8]. In humans, homozygous or
compound heterozygous G6PC3 mutations cause an auto-
somal recessive multi-system syndrome of severe congeni-
tal neutropenia type 4 (SCN4 or G6PC3 deficiency, MIM
612541) [9]. We described the extended phenotype associ-
ated with the condition [10,11], and demonstrated that
Dursun syndrome (MIM 613034) is part of this spectrum
[12]. G6PC3 mutations can also result in non-syndromic
severe neutropenia [13,14].
In the last decade, significant progress has been made
from the identification of the human ubiquitous glucose-
6-phosphatase enzyme to understanding its role in physi-
ology and disease. Here we provide an up-to-date review
of the clinical, molecular and genetic aspects of G6PC3
deficiency.
Epidemiology
Congenital neutropenia has an estimated minimum preva-
lence of 6 per million [15]. In addition to G6PC3 defi-
ciency, mutations in ELANE, GFI1, HAX1, CSF3R and
WAS are known to cause congenital neutropenia [16].n of the glucose-6-phosphatase system. Enzymes and genes are
ckets and associated disorders are highlighted in bold.
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multi-system conditions (listed under differential diag-
noses). Xia et al. studied 162 patients from the North
American severe congenital neutropenia tissue repository
[17]. In this cohort, bi-allelic pathogenic G6PC3mutations
were detected in two samples (1.2%), ELANE mutations in
55.6% of patients and no known genetic cause could be
identified in about 40% of patients. In a recent British
study of 108 kindreds that were negative for ELANE,
HAX1 and WAS mutations, four patients from three fam-
ilies were diagnosed with G6PC3 deficiency (2.8%) [14].
These two studies provide an estimate of the frequency of
G6PC3 deficiency, but the true prevalence of the condi-
tion remains unknown. To date, at least 57 patients with
G6PC3 deficiency have been described in the literature
(Tables 1, 2 and 3).Clinical description
Typical haematological features
The haematological phenotype of G6PC3 deficiency is
variable but severe neutropenia in peripheral blood
(neutrophils count below 0.5×109/L) is present in all
reported patients. Patients with G6PC3 deficiency usu-
ally present in the first few months of life with recurrent
bacterial infections although a patient presenting with
symptoms only in late teenage years has been described
[13]. Sino-pulmonary infections, otitis media, urinary tract
infections, skin abscesses and sepsis are common. Some
patients may also suffer from oral ulcers, periodontitis,
stomatitis, gingivitis and fungal infections. Untreated pa-
tients remain susceptible to bacterial infections. Nearly
two-thirds of patients with G6PC3 deficiency demonstrate
intermittent thrombocytopenia [11], but this has not been
reported to cause clinical consequences. Importantly, un-
like some other constitutional neutropenia syndromes, no
cases with myelodysplastic syndrome have been yet
reported in untreated or G-CSF treated patients with
G6PC3 deficiency. A systematic analysis has shown this to
be statistically significant [11].Atypical haematological features
In addition to the key haematological features described
above, some patients with G6PC3 deficiency can present
with additional haematological abnormalities. For ex-
ample, a sibling pair who were originally described as
the first cases of Dursun syndrome and later shown to
have G6PC3 deficiency, had severe lymphopenia and
thymic hypoplasia [12,18]. Another patient recently de-
scribed by Bégin et al. had persistent lymphopaenia [19].
Interestingly, this patient had low naïve CD4+ counts
suggesting a defect in thymic structure or function.
G6PC3 deficiency, therefore, is in the differential diagno-
sis for Di-George (velo-cardio-facial) syndrome.Bone marrow examination may show maturation ar-
rest in the myeloid lineage but some patients with
G6PC3 deficiency may have a hyper- or normo-cellular
bone marrow [20,21]. The reason for this variability in
the phenotype of G6PC3 deficiency is not clear [21] but
it emphasises the importance of considering G6PC3 de-
ficiency as a possible cause of neutropenia even if the
bone marrow does not show the maturation arrest of
the myeloid cell line.
Frequent non-haematological features
The majority of patients described with G6PC3 deficiency
have additional non-haematological features that, in a
clinical setting, help to distinguish G6PC3 deficiency from
other causes of neutropenia. Tables 1, 2 and 3 summarize
important clinical features of all 57 patients with G6PC3
deficiency described in the medical literature.
A prominent superficial venous pattern is the most
easily clinically recognizable non-haematological feature
of G6PC3 deficiency. At least 38/57 (66.6%) patients in
the medical literature have been described to demon-
strate this. We have shown that the superficial veins may
be less evident in infancy in some patients and tend to
gradually become more prominent with age [10]. In
adults these vascular changes can develop into varicose
veins and result in venous ulcers.
Forty four (77.1%) patients with G6PC3 deficiency have
been reported to have a congenital cardiac anomaly, mak-
ing it the most common non-haematological feature of
the condition. Of these 44 patients, 37 had an atrial septal
defect. Other rare heart anomalies include patent foramen
ovale, cor triatriatum, patent ductus arteriosus, critical
pulmonary stenosis and hypoplastic left ventricle. A range
of valvular anomalies, including mitral valve prolapse, in-
sufficiency or regurgitation, tricuspid insufficiency, bicus-
pid aortic valves and pulmonary valve stenosis has been
described.
Twenty five (43.8%) patients with G6PC3 deficiency
have been described to have renal system malformation
or genital anomalies. These are significantly more com-
mon in male patients (16/31) than in females (4/25). The
commonest problem in males is cryptorchidism (15/25).
Other features in males include inguinal hernia, ambi-
guous genitalia, genital dysplasia, micropenis, poor renal
cortico-medullary differentiation, hydronephrosis, small
kidneys and vesico-uretric reflux. In females, vesico-
uretric reflux, urachal fistula and genital dysplasia have
been described.
Rare non-haematological features
At least five patients, including two sibling pairs, with
G6PC3 deficiency have been described with inflamma-
tory bowel disease (IBD) [14,19,22,23]. This is in the
context of a background prevalence of IBD of one in 250
Table 1 Patients with homozygous missense G6PC3 mutation
Fam Pt.
no.

















None None None None [13,21]






None None None A single episode of myositis [14,30]




None Normocellular None None None None [14]
















proximally placed thumbs, broad
nasal bridge, pectus carinatum
and high arched palate. Died at
18 m due to severe respiratory
distress.
[12,18]
5 Turk F 18 m Lymphopenia,
monocytosis and
anemia.
Dysplastic Primary PHT since
infancy.
ASD None Diagnosed with Dursun
syndrome. Thymus hypoplasia,
proximally placed thumbs, broad
nasal bridge, pectus carinatum,
single palmar creases and high
arched palate. Died at 18 m due
to severe respiratory distress.
[12,18]
5 6 NA NA NA c.[347 T > A];




None Not described Prominent veins ASD, mild mitral and
tricuspid
insufficiency




6 7 Pak F 13 c.[347 T > C];







None None None None [13,21]





None Not described Not described ASD Not described Not described [17]
8 9 Turk* F 13 c.[461 T > C];













None Frontal bossing, depressed nasal




serum total cholesterol and LDL
cholesterol.
[27]
9 10 Turk F 12 c.[554 T > C];




None Not described Prominent veins ASD and pulmonary
valve stenosis.
None None [9]
10 11 Turk F c.[623 T > G];





























Table 1 Patients with homozygous missense G6PC3 mutation (Continued)








Prominent veins ASD and small PDA. Right gr e III VUR.
Discont ous labia
majora d minora.























Cor triatriatum None None [9]
15 Arm,
Turk





M 6 None Reduced mature
neutrophils.













Prominent veins Not reported Not rep ted Poor growth [9]
14 18 Arab,
Israel

















None None SGA, mild learning difficulties.
Hypothyroidism. Dyslipidemia




















































































Table 1 Patients with homozygous missense G6PC3 mutation (Continued)























None Not described Prominent veins ASD Urachal fistula Microcephaly [9]
18 25 White
Ger



















































laxity, mild proximal muscle
weakness and mild sensorineural
hearing loss.
[20]












Prominent veins Large ASD None Poor growth, microcephaly,
ligamentous laxity, mild proximal
muscle weakness and mild
sensorineural hearing loss.
[20]





None Maturation arrest at
myelocyte/
promyelocyte stage
Prominent veins ASD Left grade II
hydronephrosis
Triangular face, frontal bossing,
micrognathia and depressed
nasal bridge. Cutis laxa. Bilateral
























Table 2 Patients with homozygous G6PC3 truncating, frameshift and splice-site mutations
Fam Pt.
no.
















None Not described Prominent
veins
None None None [9]
23 31 Arab,
Leb




None Not described No None Cryptorchidism and
bilateral inguinal hernia.
Cleft palate [9]





None Not described None ASD None Granulomatous inflammatory bowel
disease, splenomegaly, digital clubbing
and short stature.
[14,30]
24 33 Pak F 16 None Not described None None None Granulomatous inflammatory bowel
disease, splenomegaly, digital clubbing
and short stature.
[14,30]











Small ASD None Triangular face, depressed nasal bridge,
growth retardation, growth hormone
deficiency, enlarged anterior pituitary
lobe.
[11]











ASD None Triangular face, depressed nasal bridge,
osteoporosis, Kawasaki’s disease, growth
retardation and delayed puberty.
[11]









Not described Not described [17]
28 37 Hisp M 9 c.[218 + 1G >










ASD Right inguinal hernia.
Bilateral cryptorchidism.
Frontal bossing upturned nose, recessed
chin and triangular face.
[11]













ASD Bilateral cryptorchidism Poor growth [38]
30 39 Persian M 1 c.[416G > T];
[416G > T]







ASD None None [11]
31 40 Persian M 9 m c.[416G > T];
[416G > T]*































Table 2 Patients with homozygous G6PC3 truncating, frameshift and splice-site mutations (Continued)


















Broad face, prominent ears, small nose,
big mouth, narrow forehead and short
philtrum. Mild hepatomegaly. Bilateral
inner ear hearing loss.
[11]










None Congenital ptosis and growth
retardation.
[11]













Right cryptorchidism. Sensorineural hearing loss and
prominent ears.
[28]














Crohn's disease diagnosed at 7y,
midface hypoplasia, full lips and
prognathism.
[22,23]




Crohn's disease diagnosed at 15y, mid-
face hypoplasia, full lips and
prognathism. Died at 37y due to multi-
organ failure following infective
endocarditis.
[22]









None ASD Mild VUR at 7 m
(resolved at 2y).
Triangular face, depressed nasal bridge,
growth retardation and cutis laxa.
[11]










ASD Unilateralhydronephrosis None [37]





























Table 3 Patients with compound heterozygous G6PC3 deficiency
Fam Pt.
no.










39 49 Cauc M 7 c.[131C > T];










testis, poor renal cortico-
medullary differentiation
Flat malar region, short philtrum,
splenomegaly, right ptosis
[11]











ASD Left inguinal hernia Triangular face, height and weight below
3rd centile and growth hormone deficiency.
[11]















Triangular face, prominent upper lip,
depressed tip of nose, narrow thorax,
inverted nipples and flattening of
acetabulum with the sacroiliac notch.
[11]
42 52 NA F 18 c.[326–1 G >


























Delayed puberty, Pyloric stenosis neonatally,
massive splenomegaly age 14 years
requiring removal, growth retardation.
[11]
44 54 Cauc F 16 c.[677 + 1G >
A]; [829C > T]
p.[?];
[Gln277X]
None Not described Prominent
veins
ASD None None [11]
45 55 White
French
F 13 c.[677 + 1G >
A]; [829C > T]
p.[?];
[Gln277X]
None Not described Prominent
veins
None None Myopathy [9]
46 56 White
British







None None None None [13]
57 White
British
F 18 None Not described None None None None [13]
Key for Tables 1, 2 and 3: ASD atrial septal defect, Arm Armenian, Cauc Caucasian, Eth ethnicity, Fam family, Ger German, hemat haematological, Hisp Hispanic, Le Lebanese, Mor Moroccan, MR mitral regurgitation, NA
not available, Pak Pakistani, PFO patent foramen ovale, PHT pulmonary hypertension, PS pulmonary stenosis, Pt. no. – patient number, Ref references, TR tricuspid egurgitation, Turk Turkish, VUR vesico uretric reflux;
and * denotes entries where the information is derived or corrected from the original publication. †The c.210delC mutation was described to result in p.I70fsX11 by Xia et al. However, the correct predicted protein
with this mutation should be p.I70fsX46. ‡ Please see main text for explanation for how this mutation affects the splice site.
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resembles Crohn’s disease and the intestinal pathology
of GSD1b [19]. IBD is more commonly present in indi-
viduals with other causes of neutropenia and Fernandez
et al. therefore suggested that this feature may be sec-
ondary to the neutropenia [22].
Pulmonary hypertension (PHT) has been described in
5/57 patients from three families. The diagnosis of in-
creased pulmonary arterial pressures, unrelated to con-
genital heart defect, was made in infancy in one patients
with G6PC3 deficiency [10] and in a sib-pair who were
initially described as Dursun syndrome [12,18]. In two
other patients, PHT was noted only in later life [20,22].
Interestingly, PHT is also a well recognized feature of
GSD1 [25].
Endocrine abnormalities have been described in 8/57
patients with G6PC3 deficiency. These include growth
hormone deficiency in two patients, including one with
an enlarged anterior pituitary lobe [11]. Delayed puberty,
hypogonadotropic hypogonadism or poorly developed
secondary sexual characteristics have been noted in six
patients [10,11,26,27]. Additionally, hypothyroidism was
noted in an affected brother and sister [10].
Intrauterine growth retardation, failure to thrive and
poor postnatal growth have been described in a number
of children. It is not clear if the postnatal growth retard-
ation is part of the primary phenotype or secondary to
repeated infections. Notably, female g6pc3−/− mice ex-
hibit growth retardation [8].
Some children have also been described with minor fa-
cial dysmorphism, mainly with a triangular face and a
depressed nasal bridge. Experience with adult phenotype
is limited but fullness of face may be an additional fea-
ture [10,23]. Minor skeletal and integument anomalies
have been described in a number of patients [10–12].
These include scoliosis, pectus carinatum, ligamentous
laxity, loose skin or cutis laxa, palmar erythema, small
and/or inverted nipples. Neurological and muscular fea-
tures such as microcephaly [9,20,26], sensori-neural
hearing loss [11,20,28], myopathy [9], myositis [14],
muscle weakness [20], and congenital ptosis [11] have
been described in some patients. Cleft palate or high pal-
ate has also been described rarely [9].
One family included four patients with G6PC3 defi-
ciency with mild to moderate developmental delay and
learning difficulties [10]. Intellectual deficits have not
been observed in any other patients with G6PC3 defi-
ciency and could have been coincidental to the G6PC3
deficiency in this family. In the same family one child
had raised gamma-glutamyl transferase, liver calcifica-
tions and choledocholithiasis and one adult patient had
a low HDL levels and increased amylase activity. Raised
serum cholesterol and LDL levels were recently noted in
one patient [27].Non-syndromic congenital neutropenia
At least six individuals with G6CP3 deficiency have been
described with isolated neutropenia without any other
manifestations of the disease. This suggests that more
than 10% cases of G6CP3 deficiency could be apparently
non-syndromic, although even this could be an under-
estimate due to ascertainment bias. This observation
demonstrated that G6PC3 deficiency should be consid-
ered as part of the differential diagnoses in any patient
with unexplained congenital neutropenia.
Aetiology and disease mechanism
Mutations in G6PC3 result in significantly reduced en-
zyme activity [9]. Bone marrow promyelocytes of pa-
tients with G6PC3 deficiency show increased expression
of BiP, suggesting ER stress (Figure 2) [9]. Consistent
with this, activation of the protein kinase-like ER kinase
(PERK) pathway has been demonstrated in neutrophils
of g6pc3−/− mice [29]. Neutrophils and skin fibroblasts
of patients with G6PC3 deficiency have increased rates
of apoptosis after induction with TNF-α or agents that
induce ER stress [9]. The apoptosis is mediated, in part,
by the intrinsic mitochondrial pathway [29]. G-CSF
modulates these apoptotic mediators and leads to in-
creased glucose uptake, elevated intracellular levels of
glucose-6-phosphate, lactate, and adenosine-5’-triphos-
phate in neutrophils. Additionally, decreased intracellu-
lar glucose concentration could activate GSK-3β, leading
to phosphorylation of Mcl-1 and induction of apoptosis
(Figure 2).
In addition to the decreased neutrophil numbers, dys-
function of neutrophil activity has also been demonstrated
in some patients. Hayee et al. showed severe defects in the
synthesis of N- and O- glycans in patients with G6PC3 de-
ficiency (Figure 2) [30]. Notably, they showed truncated
N-glycosylation of gp91phox, a component of nicotina-
mide adenine dinucleotide phosphate (NADPH) oxidase
found in secondary granules of neutrophils. They pro-
posed that aberrant glycosylation might underlie the di-
minished respiratory burst seen in G6PC3 deficient
granulocytes and hypothesized that the glycosylation de-
fects may also contribute towards ER stress and apoptosis.
The mechanism of aberrant glycosylation is unclear.
Hayee et al. postulated that accumulation of glucose-6-
phosphate in G6PC3 deficiency might inhibit formation of
UDP-galactose through the Leloir pathway of galactose
metabolism. However, Jun et al. have shown lower levels
of glucose-6-phosphate and lower glucose uptake in cells
of g6pc3−/− mice [31].
Some patients with G6PC3 deficiency paradoxically
demonstrate normal or hypercellularity of the bone mar-
row. McDermott et al. studied such a sibling pair and
showed increased expression of CXCR4 in neutrophils
[20]. They proposed that in such patients, stress induces
Figure 2 A flow diagram summarising proposed mechanisms of haematological features of G6PC3 deficiency. G6PC3 deficiency leads to
decreased cytoplasmic glucose and glucose-6-phosphate levels [31] and ER stress and activation of protein like ER-kinase (PERK) [9,29]. The lower
levels of glucose possibly lead to activation of GSK-3β and phosphorylation of Mcl-1. Activation of these pathways contributes to apoptosis of the
cells (this part of the pathway is shown in blue boxes). G6PC3 deficiency also results in aberrant glycosylation of a NADPH oxidase subunit,
gp91phox (shown in green box). The precise mechanism of aberrant glycosylation is not clear but may be mediated by perturbation of the Leloir
pathway of galactose metabolism (shown in faded green). The final effect of these dysfunctions is maturation arrest of neutrophils, neutropenia
and diminished respiratory burst (shown in red boxes).
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egression or premature return of granulocytes to the bone
marrow for destruction. They also showed in g6pc3−/−
mice that a specific CXCR4 antagonist, AMD3100, rapidly
reversed neutropenia.
The immune problems of G6PC3 deficiency extend
beyond neutrophil dysfunction. Jun et al. demonstrated
impaired macrophage respiratory burst, chemotaxis, cal-
cium flux and phagocytic activities with down-regulation
of reduced NADPH oxidase subunits and membrane
translocation of p47phox, [31].
Molecular diagnosis and the mutational spectrum
of G6PC3
Summary of mutations
G6PC3 maps to 17q21.31, consists of six exons and en-
codes the G6PC3 protein that is comprised of 346 resi-
dues and is anchored in the ER by nine transmembrane
helices in a way that keeps the active site inside the ER
lumen [5,6]. Histidine at position 167 is the phosphate
acceptor site and arginine at 79 and histidine at 114 are
proton donors [32]. The signature phosphatase motif,
K-X6-RP-(X12-54)-PSGH-(X31-54)-SR-X5-H-X3-D, spans be-
tween residues 66 and 171 of G6PC3.G6PC3 deficiency can be diagnosed by sequencing all
the six exons of the gene (NM_138387.3). There are now
at least 57 patients with genetically proven G6PC3 defi-
ciency described in the literature (Tables 1, 2 and 3). Of
the 114 mutated alleles, 66 are missense (Figure 3). Four-
teen G6PC3 missense mutations resulting in amino acid
substitutions in nine different codons have been identified.
These missense mutations are spread all across the gene
but no missense mutation has been described in exon 2.
The largest number of mutated missense alleles have been
described in exon 6. The other 48/114 mutated G6PC3 al-
leles result from four nonsense mutations, seven frame-
shift deletions or insertions and four splice-site mutations.
Of note, the c.416G > T mutation has been identified in
two patients and predicted to be a missense change
(p.S139I) [11,27]. However, the codon for residue S139 is
determined by the last two nucleotides of exon 3 and the
first nucleotide of exon 4. The nucleotide change respon-
sible for p.S139I is c.416G > T and is the last nucleotide of
exon 3. Hence, it is possible that this change, in fact, af-
fects splicing. The resultant protein has not been charac-
terized and NNsplice software predicts the spice donor
site in the wild-type sequence is lost with c.416G > T [33].
We have, therefore, considered c.416G > T as a splice-site
mutation in our analysis.
Figure 3 A summary of G6PC3 mutations. A schematic representation of the G6PC3 gene. The starting and ending nucleotide numbers of the
cDNA and their corresponding amino acid residue numbers are provided within each exon. Each mutation is represented once for every family in
which it was detected. The inverted triangles represent missense mutations, the block-arrows represent splice-site mutations and stars represent
truncating or frame-shift mutations. UTR is untranslated region.
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To date, a number of G6PC3 mutations have been iden-
tified more frequently in particular ethnic groups. The
homozygous p.P44S mutation has been described in
three unrelated Pakistani patients and in two of these
patients it was confirmed to be present on a common
haplotype [14]. Ten patients, from four unrelated fam-
ilies, with the homozygous p.R253H mutation have been
ascertained from different countries in the Middle East,
suggesting that p.R253H may be a founder mutation in
this population. Seven patients from six families with the
homozygous p.G260R mutation have a White European
ancestry. Two patients with compound heterozygous
mutations also have p.G260R as one of the changes
suggesting that it is an ancient European founder muta-
tion in Caucasians. Other mutations described in mul-
tiple unrelated patients from particular ancestry include
p.G277X in Europeans, p.N313fs in Persians and
p.I70fsX46 in Hispanic patients.
Functional prediction of G6PC3 mutations
The mechanism by which G6PC3 missense mutations
lead to loss of enzyme activity remains unclear. Notably,
the protein structure of G6PC3 has not been defined.
G6PC3 is a paralog of G6PC and the two genes, along
with G6PC2, are thought to have arisen from ancient
duplication events [34]. The structure of liver glucose-6-
phosphatase (coded by G6PC) is better characterized
[35]. Due to their similarities, G6PC may serve as a use-
ful model for studying G6PC3 [5,6]. The G6PC molecule
is constituted from 357 amino acids (in contrast with
346 for G6PC3) and 120 of 346 (~35%) amino acids are
identical between the two molecules.Out of the nine sites substituted in patients with
G6PC3 deficiency, five amino acids (P44, M116, T118,
R161 and G260) demonstrate complete conservation
between G6PC3 and G6PC amino acid sequences
(Figure 4). One residue, R253, is semi-conserved and
three are not conserved (L154, L185 and L208). Further-
more, three G6PC3 mutants with reduced enzyme activ-
ity that have not been demonstrated in patients, but
were created in the laboratory (R79A, H114A and
H167A), also affect fully conserved sites [32]. Six out the
nine residues affected by missense G6PC3 mutations are
fully conserved in orthologs till the level of Xenopus
(P44, M116, T118, R161, R253 and G260) (Figure 5).
L154 is conserved till Drosophila and L185 and L208 are
identical in human and mouse. All the active site resi-
dues are fully conserved.
In GSD1a, 54 G6PC missense mutations resulting in
substitution of 48 residues have been reported [36]. Out
of these 48 residues, 29 are completely conserved be-
tween G6PC and G6PC3 (Figure 4). Combining the
G6PC and G6PC3 missense mutations data, 33 of 120
highly conserved and only 20 of 226 semi-conserved or
non-conserved residues are substituted due to a mis-
sense mutation in either GSD1a or G6PC3 deficiency.
This difference is statistically significant (p < 0.0001, cal-
culated by Fisher’s exact test). Hence, it is likely that the
protein structure, the mutation spectrum and the mo-
lecular mechanisms underlying missense mutations in
the two diseases are comparable.
G6PC missense mutations have been classified into
those affecting active site, helical and non-helical de-
pending on their predicted topological position [36].
Studies have demonstrated that active site mutations
Figure 4 G6PC3 and G6PC alignment and known missense mutations. A ClustalW alignment of G6PC3 and G6PC amino acid sequences.
Identical residues are marked by *. Sites where missense mutation has been identified in G6PC3 are highlighted by red arrows. Green arrows
highlight missense mutations in GSD1a. The conserved residues are enriched in missense mutations described in two diseases.
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stability. The majority of the helical substitutions
destabilize the mutant protein because the integrity of
trans-membrane helices is critical for correct folding
and stability. Moreover, the non-helical regions of G6PC
have been shown to be less important for enzyme stabil-
ity and activity.
Mapping known missense G6PC3 mutations on the
predicted protein structure shows that all nine missense
mutations are predicted to be helical (Figure 6). Hence
analogous to findings in G6PC, we predict the nine
known G6PC3 mutations result in decreased enzyme
stability and loss of function.
The mutation data additionally highlights the import-
ance of certain critical G6PC3 residues. For example,
four different substitutions affecting residue number 116
(p.M116V, p.M116K, p.M116T and p.M116I) have been
reported in five patients with G6PC3 deficiency
(Figure 3). Similarly, two different substitutions have
been detected affecting residue 44 in three patients
(p.P44S and p.P44L), with p.P44S detected in two unre-
lated Pakistani patients.
Truncating mutations can result in nonsense-mediated
decay of the transcript, or in formation of a non-
functional aberrant protein. In autosomal recessive dis-
orders, therefore, patients homozygous for truncating
mutations are predicted to have a complete absence of
the protein encoded by the mutated gene. At least 19patients with bi-allelic truncating G6PC3 mutations (ex-
cluding splice-site mutations) have been described to
date (Table 2). If mutations in these patients result in
complete absence of G6PC3 enzyme activity, then clearly
it is compatible with life in humans. However, studies of
enzyme activity have not yet been reported in any pa-
tients with truncating G6PC3 mutations. Moreover,
current evidence does not indicate that patients with bi-
allelic truncating G6PC3 mutations have a more severe
phenotype than most patients with missense G6PC3 mu-
tations. Another possibility is that an alternative in-frame
translation start site could be used in patients with trun-
cating mutations. In this context, it is interesting to note
that apart from p.E86fs, all truncating G6PC3 mutations
cluster in in exons 1, 5 or 6, which flank the exons coding
for the phosphatase activity. This is in contrast with
G6PC3 missense mutations that are spread across all
exons. Without evidence from functional work it is impos-
sible to conclude if this observation has a functional basis
or if it is an incidental finding.
The truncating mutation closest to the carboxy-
terminal of the G6PC3 protein is p.M334fs. This muta-
tion has not been characterised functionally but it is
predicted to result in read through of additional amino
acids and not cause premature termination of the pro-
tein. Exploration of the mechanism in this mutation
could provide insight about the role of terminal residues
of the protein.
Figure 5 G6PC3 multi-species alignment. Multi-species ClustalW alignment of G6PC3. Identical residues are marked by *. Sites where missense
mutation has been identified in G6PC3 are highlighted by red arrows. Amino acids in trans-membrane regions are shown under lines of different
colours. Note that all the missense mutations affect trans-membrane residues.
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We have shown absence of a genotype–phenotype rela-
tionship for the bone marrow phenotype in patients with
G6PC3 deficiency [21]. However, our recent work has
suggested that the extended phenotypic spectrum may
depend on the genotype of the patients [13]. Specifically,
certain mutations e.g. p.P44S seem to be more often as-
sociated with non-syndromic neutropenia with absence
of other systemic features. This hypothesis is based on a
small number of patients and additional patients need to
be identified to test it.
Differential diagnosis
Congenital neutropenia is a genetically and phenotypic-
ally heterogeneous group of conditions. Broadly, these
conditions can be divided into those where neutropenia
is the predominating feature, such as in ELANE, GFI1,
HAX1, CSF3R and WAS mutations and those whereneutropenia is part of a multi-system disorder. The later
group includes glycogen storage disorder type 1b,
Schwachman-Diamond syndrome, WHIM syndrome,
Barth’s disease, Chediak-Higashi syndrome, Hermansky-
Pudlak syndrome type 2, Griscelli syndrome type 2, P14
deficiency, Clericuzio poikiloderma with neutropenia,
Pearson syndrome, Cohen syndrome, cartilage-hair hypo-
plasia and Charcot-Marie-Tooth disease type 2 M [16].
Management
Neutropenia of a number of patients with G6PC3 defi-
ciency has been treated with G-CSF. It leads to improve-
ment in neutrophil numbers, prevents infections and
improves quality of life [9,11,20]. However, in some pa-
tients G-CSF may fail to control infections even in large
doses [14]. On the other hand, mildly affected patients
may not necessarily require G-CSF treatment and can be
managed with prophylactic antibiotics. T-cell subsets
Figure 6 Predicted topology of G6PC3 with missense mutations. Residues substituted by missense mutation are highlighted by red circles
and the laboratory generated substitutions by blue circles. The S139 residue, predicted in previous publications to be substituted by c.416G > T
mutation is highlighted by purple circle. Our analysis suggests that the c.416G > T might be a splice-site mutation (see main text for discussion).
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ciency is suspected.
Echocardiogram, renal and pelvic ultrasound scans
should be performed in all cases of suspected or con-
firmed G6PC3 deficiency. Expert advice in management
of congenital heart defects and genito-urinary problems
must be sought. Patients, especially adults should be
monitored for development of varicose veins and venous
ulcers. Growth parameters should be monitored in all
children with G6PC3 deficiency. If indicated, evaluation of
growth hormone levels in children and pubertal develop-
ment in adolescents should be considered. Biochemical
profile monitoring could be part of routine part of the
follow-up. Of note, raised total serum cholesterol and
LDL levels were reported to normalize with statins in one
patient [27]. Rare manifestations such as PHT and IBD
should be managed according to standard guidelines. One
patient with G6PC3 deficiency and IBD required a right
hemi-colectomy and showed good response to anti-TNF
treatment, infliximab [19]. The authors suggested consid-
ering bone marrow transplantation for patients with
G6PC3-related IBD refractory to anti-TNFα therapy.
Prognosis
Prognosis of most patients with G6PC3 deficiency is
generally good on G-CSF treatment or prophylactic anti-
biotics in mildly affected individuals. However, untreatedG6PC3 deficiency can be fatal. Both patients with
Dursun syndrome died at 18 months due to severe re-
spiratory distress [12,18]. The oldest patient ever de-
scribed with G6PC3 deficiency died at 37 years of age
due to infective endocarditis [22]. Of note this patient
was non-compliant with his treatment. The youngest
reported death in a patient with G6PC3 deficiency was
at nine months due to severe lung infection [37].
Unresolved questions
A number of questions remain to be answered in
G6PC3 deficiency. Identification of more patients is re-
quired to clarify the extended phenotypic spectrum
of the disease and the possible genotype-phenotype
relationship. Although no cases of myelodysplastic
syndrome have yet been noted in G6PC3 deficiency, long-
term follow-up will be required to confirm this observa-
tion. At present, the reason for variability of the bone
marrow phenotype in patients with mutations in G6PC3
is uncertain and further characterisation is warranted.
Understanding the molecular basis of mutations leading
to loss of enzyme activity may help to explore the thera-
peutic potential of small molecule chaperones in this
disease, especially because missense mutations affect the
majority of patients with G6PC3 deficiency. Further-
more, a similar approach may also benefit patients with
GSD1a. Much work has been undertaken to understand
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mechanisms underpinning the developmental defects of
other organs and other haematological lineages in the
condition remain to be studied.
Conclusions
In this review we have compiled the clinical features of
all the 57 patients with G6PC3 deficiency described in
the literature demonstrating the variability of the condi-
tion. This will help in management of patients and in
genetic counselling of families. G6PC3 deficiency should
be part of the diagnostic screen of any patient with se-
vere congenital neutropenia. Analysis of mutational
spectrum provides insights into the disease mechanism
and reveals a possible genotype-phenotype relationship.
Endnote
aNote – G6PC3 gene is incorrectly mapped to ORPHA486
(autosomal dominant severe congenital neutropenia) on
www.orpha.net.
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